Sebastien Benzekry
About Sebastien Benzekry
Sebastien Benzekry is the Head of the Inria-Inserm team COMPO, specializing in computational pharmacology and clinical oncology. He has worked at Inria since 2013, focusing on predicting metastatic relapse and developing simulation tools for clinical trials.
Work at Inria
Sebastien Benzekry has been a Scientific Researcher (CR1) at Inria since 2013, contributing to the field of computational pharmacology and clinical oncology for over 11 years. In 2021, he became the Head of the Inria-Inserm team COMPO, which focuses on integrating statistical methods and machine learning algorithms with mechanistic modeling. His leadership involves guiding a multidisciplinary team that includes clinical oncologists, pharmacologists, and mathematicians, emphasizing model-guided clinical trials and personalized oncology.
Education and Expertise
Sebastien Benzekry studied at École Normale Supérieure, where he achieved a Magistère de Mathématiques from 2004 to 2007. He further developed his expertise at Aix-Marseille Université, where he worked as a Doctorant from 2008 to 2011. His academic background provides a strong foundation for his current research, particularly in the application of mechanistic learning to predict metastatic relapse and optimize clinical trial designs.
Background
Before his tenure at Inria, Sebastien Benzekry held positions at École Normale Supérieure de Cachan as a Normalien from 2007 to 2009 and at École normale supérieure as a Magistérien from 2004 to 2007. These roles contributed to his development in mathematical sciences and laid the groundwork for his research in computational pharmacology and oncology.
Research Focus
Sebastien Benzekry's research primarily focuses on predicting metastatic relapse, especially in early-stage breast cancer. He develops simulation tools aimed at optimizing the design of combinatorial clinical trials. His work also includes predicting individual responses, relapses, and progression patterns in patients treated with immune checkpoint inhibitors, particularly in non-small cell lung cancer (NSCLC).
Leadership and Team Collaboration
As the Head of the Inria-Inserm team COMPO, Sebastien Benzekry leads a multidisciplinary team that collaborates closely with clinical oncologists, pharmacologists, and mathematicians. This collaborative approach is essential for conducting model-guided clinical trials and advancing personalized oncology, ensuring that research is grounded in both theoretical and practical applications.